The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Rare driver mutations could refine diagnosis and management of myeloproliferative neoplasms
Gonzalo Carreño Gómez-Tarragona, MD, PhD, 12 de Octubre University Hospital, Madrid, Spain, discusses preliminary results from the ELN MPN-OLIVETTI study, exploring rare JAK2, CALR, and MPL variants and how improved genetic characterization may refine diagnosis, prognosis, and management of patients with myeloproliferative neoplasms. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
